{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Overall"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Follow-up period"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months","title":"Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products","type":"SECONDARY","unitOfMeasure":"Participants"}